EMSTER KURT VON

SEC source: 0001213900-26-085189 · ownership.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Voting Common Stock · 7,500 shares

Expires 2036-07-31

F1 · derivative.exercise_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.

F1 · derivative.expiration_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.

SEC source: 0001213900-25-061501 · ownership.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Voting Common Stock · 7,500 shares

Expires 2035-07-03

F1 · shares: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders.

SEC source: 0001213900-24-051398 · ownership.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Voting Common Stock · 7,500 shares

Expires 2034-06-06

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 13

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,010 shares

Expires 2034-01-23

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 12

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2033-01-24

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 11

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 67,000 shares

Expires 2032-01-24

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 10

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 32,000 shares

Expires 2031-01-25

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 9

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 49,245 shares

Expires 2030-05-14

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 8

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 27,705 shares

Expires 2029-01-28

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 7

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2028-01-23

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 6

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2027-09-21

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 5

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2027-06-27

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 4

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2026-06-27

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 3

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2025-06-23

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · derivative · entry 2

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2025-01-06

F2 · price: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

SEC source: 0000950170-24-035435 · ownership.xml · nonDerivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.

SEC source: 0001062993-24-001416 · form4.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,010

Underlying: Common Stock · 14,010 shares

Expires 2034-01-23

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2024.

SEC source: 0001062993-23-018622 · form4.xml · derivative · entry 7

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,249 shares

Expires 2024-01-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vested as to 1/3 of the underlying shares on January 6, 2014 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.

SEC source: 0001062993-23-018622 · form4.xml · derivative · entry 6

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,372 shares

Expires 2023-12-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The incentive award (the "Award") was granted under the CymaBay 2013 Equity Incentive Plan and could be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The shares subject to the Award vested in 48 equal monthly installments from the grant date.

SEC source: 0001062993-23-018622 · form4.xml · derivative · entry 5

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 943 shares

Expires 2023-12-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vested as to 1/4 of the underlying shares on April 2, 2010 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter.

SEC source: 0001062993-23-018622 · form4.xml · derivative · entry 4

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,357 shares

Expires 2023-10-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested as to 1/3 of the underlying shares on October 31, 2013 and the remaining 2/3 of the underlying shares vested ratably on a monthly basis over the 48 months thereafter.

SEC source: 0001062993-23-018622 · form4.xml · nonDerivative · entry 2

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,000

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 30, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.54 to $15.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001062993-23-018622 · form4.xml · nonDerivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,921

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001213900-23-047571 · ownership.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,000

Underlying: Voting Common Stock · 47,000 shares

Expires 2033-06-07

SEC source: 0001213900-23-029900 · ownership.xml · nonDerivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,175

F1 · shares: These shares were sold by the Reporting Person solely in order to satisfy certain tax obligations in connection with the issuance of shares of the Issuer's common stock upon the vesting of restricted stock units.

SEC source: 0001062993-23-001499 · form4.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-01-24

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2023.

SEC source: 0001213900-22-063945 · ownership.xml · nonDerivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,250

F1 · shares: The reported securities are represented by restricted stock units (the "RSU Award"), 1/2 of which shall vest on each of April 12, 2023 and October 12, 2023, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

SEC source: 0001213900-22-014569 · ownership.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,045

Underlying: Voting Common Stock · 78,045 shares

Expires 2032-03-21

F1 · derivative.exercise_date: 1/3rd of the shares subject to the option (the "Option") shall vest on December 7, 2022, and 1/3rd of the shares subject to the Option shall vest on each anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

F2 · ownership.direct: The Reporting Person is a member of the investment committee of Abingworth Bioventures VII, LP ("ABV VII") which approves investment and voting decisions by majority vote. Abingworth LLP provides advisory services to ABV VII and exercises investment and dispositive power over the securities held by ABV VII. Under an agreement between the Reporting Person and Abingworth LLP, the Reporting Person is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of Abingworth LLP.

F3 · ownership.direct: ABV VII may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, Abingworth LLP, ABV VII or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001062993-22-001694 · form4.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 67,000 shares

Expires 2032-01-24

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2022.

SEC source: 0000905718-21-000752 · vaxcyte_fm4jun22021.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock, $0.001 par value per share · 15,000 shares

Expires 2031-06-01

F1 · derivative.exercise_date: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

F2 · ownership.direct: The Reporting Person is a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP.

F3 · ownership.direct: ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-21-033806 · doc4.xml · derivative · entry 4

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,187,504 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F2 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F2 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F3 · ownership.nature: The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8.

F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-21-033806 · doc4.xml · nonDerivative · entry 3

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,960,231

F3 · ownership.nature: The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8.

F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-21-033806 · doc4.xml · nonDerivative · entry 2

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,187,504

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F3 · ownership.nature: The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8.

F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-21-033806 · doc4.xml · nonDerivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,828

F1 · price: The price reported is a weighted-average price. The shares were purchased at prices ranging from $11.60 to $12.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-21-033335 · doc4.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,925

Underlying: Class A Common Stock · 9,925 shares

Expires 2031-05-12

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders.

SEC source: 0001333277-21-000028 · edgar.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2031-01-25

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from January 1, 2021.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · derivative · entry 9

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 298,917 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.exercise_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.expiration_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · derivative · entry 8

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 454,812 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.exercise_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.expiration_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · derivative · entry 7

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 1,217,074 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.exercise_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.expiration_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · derivative · entry 6

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

Underlying: Common Stock, $0.001 par value per share · 2,185,415 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.exercise_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F3 · derivative.expiration_date: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · nonDerivative · entry 5

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,168,718

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · nonDerivative · entry 4

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,156,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · nonDerivative · entry 3

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,857,301

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · nonDerivative · entry 2

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,402,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000595 · vaxcyte_fm4jun1620.xml · nonDerivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,185,415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.

F1 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

SEC source: 0000905718-20-000580 · vaxcyte_fm4jun1120.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock, $0.001 par value per share · 40,000 shares

Expires 2030-06-10

F1 · derivative.exercise_date: 1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter.

F2 · ownership.direct: The Reporting Person is a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP.

F3 · ownership.direct: ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0000905718-20-000586 · vaxcyte_fm4ajun1520.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock, $0.001 par value per share · 40,000 shares

Expires 2030-06-10

F1 · derivative.exercise_date: 1/3 of the shares of Common Stock subject to the option vest on June 11, 2021, and 1/36 of the shares vest monthly thereafter.

F2 · ownership.direct: The Reporting Person is a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP.

F3 · ownership.direct: ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001209191-20-038529 · doc4.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,245

Underlying: Common Stock · 49,245 shares

Expires 2030-05-14

F1 · derivative.exercise_date: The shares subject to the option shall vest in 12 equal monthly installments commencing on January 31, 2020, subject to the Reporting Person's continuous service to the Issuer as of each such date.

SEC source: 0000905718-19-000089 · ownership.xml · derivative · entry 1

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,705

Underlying: Common Stock · 27,705 shares

Expires 2029-01-28

F1 · derivative.exercise_date: The Option vests as to 1/12 of the underlying shares monthly from January 1, 2019.

SEC source: 0000905718-18-000979 · cymabaytherafm4_dec172018.xml · nonDerivative · entry 2

EMSTER KURT VON · CIK 0001252524 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 131,036

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.24 to $8.10 per share, inclusive.

F2 · price: The Reporting Person undertakes to provide to Cymabay Therapeutics, Inc. ("Issuer") any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F3 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.